People with diabetes who take a class of drugs known as sodium–glucose cotransporter 2 (SGLT2) inhibitors will now need …
Invokana
Invokana May Increase Risk of Leg and Foot Amputations
The FDA issued a safety communication alerting the public about interim safety results from an ongoing clinical trial th…
FDA Revises Labels of SGLT2 Inhibitors
A U.S. FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines …
Invokana Warning: Diabetes Drug May Increase Risk of Bone Fractures
Several months ago the FDA warned that SGLT2 inhibitors like Invokana may cause diabetic ketoacidosis, a condition that …
How Invokana Works: New Type 2 Diabetes Drug Hailed as a Major Treatment Advance
“The bottom line with this drug is that it controlled blood sugar levels without causing weight gain and caused almost n…
FDA Approves Janssen’s Invokana, the First in a New Class of Type 2 Diabetes Medication
The FDA has approved Janssen Pharmaceutical's new type 2 diabetes treatment, Invokana (canagliflozin). Invokana is the …
